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Reactive nitrogen species such as peroxynitrite can nitrate specific amino acids, whether free
or protein bound, and 3-nitrotyrosine is believed to be one marker of this reaction. To examine
the significance of this pathway in biological systems we have developed an accurate,
sensitive, and specific assay for 3-nitrotyrosine based on combined liquid chromatography
tandem mass spectrometry. Our approach allowed simultaneous analysis of both tyrosine and
3-nitrotyrosine and employs isotopomer standards (i.e., [15N1,
13C9]-tyrosine and [
13C6]-3-
nitrotyrosine). Calibration curves were linear (r2 5 0.999) across the range 0.5–100 pg/mL
(i.e., 2.2–442 fmol/mL), and the detection limit for standard samples was 0.5 pg/mL (2.2
fmol/mL, or 10 fmol on column; S/N 5 5) or 1 pg/mL (4.4 fmol/mL) for extracted (biological)
samples. As a component of this study we have undertaken an extensive investigation of
artifactual formation of 3-nitrotyrosine under conditions that exist during sample extraction
and derivatization. Our studies show that under appropriate conditions (low pH, elevated
temperatures, and in the presence of a vast excess of the two substrates, tyrosine and the
nitrate anion), 3-nitrotyrosine can readily be formed as an artifact. (J Am Soc Mass Spectrom
2000, 11, 578–586) © 2000 American Society for Mass Spectrometry
Nitrogen monoxide (nitric oxide, NO
z) is a free
radical cellular messenger involved in the reg-
ulation of several physiological and pathologi-
cal processes. Inflammatory and pathological degener-
ation of tissue has been, in part, ascribed to NOz
interacting with superoxide to form the reactive per-
oxynitrite anion (ONOO2) [1]. Specific amino acids
within peptides and proteins can react with ONOO2 to
form both oxidized and nitrated residues, thereby com-
promising the integrity and function of the protein [2].
Although there are multiple targets for the reactive
ONOO2, the presence of 3-nitrotyrosine, whether free
or protein bound, has been proposed as a marker of
ONOO2 formation (and action) [3]. However, little is
known of the status of circulating 3-nitrotyrosine, the
extent to which it normally occurs, and how much
might be of dietary origin.
Beckman and co-workers have developed an immu-
nohistochemical method, using specific antibodies to
3-nitrotyrosine, to detect and localize nitrated proteins
in several diseases and pathological conditions [4–8],
but few methods for quantifying trace amounts of
3-nitrotyrosine in physiological fluids or protein hydro-
lysates have been reported [9]. Kamisaki et al. [10] used
precolumn derivatization of 3-nitrotyrosine in an high
performance liquid chromatography ultraviolet (HPLC-
UV) technique and reported a detection limit of 100
fmol (22.6 pg). Shigenaga et al. [11] used an indirect
procedure in which 3-nitrotyrosine is converted to
N-acetyl-3-aminotyrosine which is then assayed using
HPLC with electrochemical detection. This latter assay
gave a limit of detection of approximately 20 fmol (4.5
pg) on column. Ohshima and colleagues [11] have also
developed a novel HPLC-based analysis that employs
reduction of 3-nitrotyrosine to 3-aminotyrosine on a
platinum column. They report a detection limit of 100
fmol per sample. Presumably because of difficulties
associated with the development of suitable derivatiz-
ing conditions, few assays have been reported that are
based on mass spectrometry [11]. An assay based on gas
chromatography-electron capture negative ion (GC-
ECNI) mass spectrometry has been reported, albeit with
a limit of detection of ,1 nmol (226 ng) [12]. More
recently Crowley et al. reported a GC-ECNI-MS assay
for 3-nitrotyrosine with enhanced sensitivity (i.e., a
limit of quantification of ;400 amol or ;100 fg on
column). Here the analysis is based on the determina-
tion of 3-aminotyrosine generated by the reduction of
3-nitrotyrosine [13]. Recently, and of special note,
Schwedhelm et al. [14] adopted gas chromatography
combined with tandem mass spectrometry to quantify
free 3-nitrotyrosine in human plasma. They report a
limit of quantification of 125 pM.
Our early attempts to develop a quantitative assay
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for 3-nitrotyrosine were fraught with problems and
there was good evidence to indicate artefactual forma-
tion of the compound during sample work up. The
current investigation was aimed at developing a
method free from artifactual formation that would
allow accurate quantification of 3-nitrotyrosine in phys-
iological tissues and fluids. The method was then
applied to the determination of 3-nitrotyrosine levels in
a range of biological samples.
Experimental
Materials. [15N1,
13C9]-L-Tyrosine and [
13C6]-L-tyrosine
were obtained from Cambridge Isotope Laboratories
(Andover, MA). 3-Nitro-L-tyrosine, L-tyrosine, tetra-
nitromethane, trifluoroacetic anhydride, and trifluoro-
ethanol were obtained from Sigma-Aldrich (Castle Hill,
NSW Australia). Throughout this work solvents and
chemicals of reagent (or analytical) grade were em-
ployed. These were obtained from commercial suppli-
ers and were used as supplied (i.e., without further
purification).
Preparation of the internal standard. [13C6]-3-Nitroty-
rosine was prepared by reacting solutions of the corre-
spondingly labeled L-tyrosine (50 mg; tris buffer, 5 mM,
pH 8.0, 300 mL) with tetranitromethane (0.5 mL) for 5
min. Trifluoroacetic acid (200 mL) was added and, after
mixing, the solution was washed with toluene (4 3 0.5
mL) to remove residual organic-soluble nitrating spe-
cies. The product was then retained on a C18 Sep-Pak
cartridge and eluted as described (see below). Com-
bined gas chromatography (GC)/MS analysis of a de-
rivatized aliquot (full scan mode) indicated the yield of
labeled 3-nitrotyrosine to be about 80%. Based on peak
areas for the molecular anions (m/z 410 and 404),
unlabeled ([12C6]-3-nitrotyrosine was present to the
extent of 0.7%. The final solution, containing approxi-
mately 40 mg (172 nmol) of [13C6]-3-nitrotyrosine, was
diluted with water (to 1 mL) and aliquots (50 mL) were
stored for use in the quantification of 3-nitrotyrosine.
Solid phase extraction of 3-nitrotyrosine. 3-Nitrotyrosine
and tyrosine were extracted from samples using C18
Sep-Pak cartridges (Waters of Australia, Rydalmere,
Australia). The cartridges were preconditioned by the
addition of 5 volumes of a mixture of acetonitrile
(CH3CN), water, and trifluoroacetic acid (90 : 9.9 : 0.1)
and then washed with aqueous trifluoroacetic acid
(TFA, 0.1%, 5 volumes). Sample mixtures were treated
with aqueous TFA (10%) to reduce their pH to below 7
and were then loaded onto the Sep-Pak cartridge. The
cartridge was then washed with aqueous TFA (0.1%, 5
volumes) and then tyrosine and 3-nitrotyrosine were
recovered with a yield of 90% by elution with CH3CN :
H2O : TFA (90 : 9.9 : 0.1, 1 mL).
Derivatization of 3-nitrotyrosine and tyrosine. To impart
sufficient volatility to allow gas chromatography, both
3-nitrotyrosine and tyrosine were derivatized by con-
version to their trifluoroacyl/trifluoroethyl esters: solu-
tions or samples containing L-tyrosine or 3-nitro-
tyrosine, together with appropriate isotopomers, were
dried under reduced pressure (Speed Vac., Savant In-
struments, Farmingdale, NY) and the residue was
heated (70 °C, 30 min.) in the presence of trifluoro-
ethanol (TFE, 50 mL) and trifluoroacetic anhydride
(TFAA, 200 mL). Excess reagents were then removed
under a stream of nitrogen and the residue dissolved in
an appropriate volume of toluene (usually 200 mL,
containing 0.1% TFAA) and injected (1 mL) onto the GC
column.
Extraction of 3-nitrotyrosine from plasma. Levels of free
3-nitrotyrosine were determined in human plasma col-
lected from healthy volunteers. Plasma (100 mL) and
[13C6]-3-nitrotyrosine (20 mL, 8.8 pmol or 2 ng) were
mixed and then subjected to solid phase extraction on a
C18 Sep-Pak (see above). The eluted fraction was dried
under reduced pressure (Speed Vac) and derivatized
(see above) in preparation for GC/MS analysis. {For
some samples [15N1,
13C9]-L-tyrosine (;10.5 nmol or 2
mg) was added to the extraction to measure tyrosine
nitration during the derivatization step.}
Nitration of tyrosine by nitrate. Varying amounts (0–40
nmol) of sodium nitrate dissolved in water (100 mL)
were added to aqueous aliquots of tyrosine (5 nmol, 10
mL) and the solutions evaporated to dryness under
reduced pressure (Speed Vac). Each residue was heated
in a capped vial with a mixture of TFAA (200 mL) and
TFE (50 mL). Samples were then taken to dryness under
nitrogen and the residue reconstituted in toluene as
detailed above.
Preparation of Biological Samples for LC/MS
Analysis
Plasma and urine. After the addition of [13C6]-labeled
3-nitrotyrosine (8.8 pmol or 2 ng), and [15N1,
13C9]-
labeled tyrosine (10.5 nmol or 2 mg), samples (100 mL)
were desalted on C18 Sep-Pak cartridges (Waters) as
described above. After extraction and drying the sam-
ples were reconstituted in water (100 mL) ready for
LC/MS/MS analysis.
Synovial fluid. Samples were collected from patients
with either active rheumatoid arthritis (RA, n 5 5) or
osteoarthritis (OA, n 5 2). The fluid samples (100 mL)
were centrifuged (13,000 g, 10 min) to sediment cells,
the internal standards, [13C6]-Labeled 3-nitrotyrosine (2
ng or 8.8 pmol) and [15N1,
13C9]-labeled tyrosine (2 mg
or 10.5 nmol) were then added to the supernatant, and
the protein precipitated by the addition of acetone (1
mL). Samples were again centrifuged (13,000 g, 15 min).
The supernatant was dried under reduced pressure and
reconstituted in water (100 mL) ready for LC/MS/MS
analysis.
Tissue samples. Heart muscle tissue (;100 mg) was
collected from three month old rats (n 5 6). The tissue
was suspended in buffer A [5 mL; 50 mM Na2HPO3 at
pH 7.3 containing diethylenetriaminepentaacetic acid
(100 mM), and butylated hydroxytoluene (100 mM)] and
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homogenized (at 4 °C) using a mechanical tissue ho-
mogenizer. Samples were then centrifuged (13,000 g, 10
min) and the supernatant collected and evaporated to
dryness (Speed Vac). The residue was reconstituted in
buffer A (100 mL) and then acetone (1 mL) was added to
precipitate proteins. The tubes were again centrifuged
(13,000 g, 15 min), the supernatant discarded, and the
pellet washed with acetone (32). The protein pellet was
then transferred to a hydrolysis tube and subjected to
gas phase acid hydrolysis [15]. The hydrolyzed sample
was passed through a C-18 Sep-Pak cartridge, evapo-
rated to dryness, and then reconstituted in water (200
mL) prior to injection into the HPLC system. An aliquot
of these same samples was also taken to dryness and
derivatized with TFAA/TFE prior to GC/MS analysis.
Mass Spectrometry
GC-MS equipment and operating conditions. Gas chroma-
tography-mass spectrometry was performed on a
Hewlett-Packard 5890 gas chromatograph interfaced to
a Hewlett-Packard 5989B mass spectrometer. To extend
capillary column life, the GC inlet port was fitted with
a 4 mm deactivated liner packed with 110 mg of 3%
SP-2100 on 100/120 mesh Supelcoport (Sigma-Aldrich,
Castle Hill, Australia); the packed liner was replaced
prior to each assay. Chromatographic separations were
performed in splitless mode using an HP-5MS capillary
column (30 m 3 0.25 mm i.d. with 0.25 mm stationary
phase film thickness, Hewlett-Packard, Australia). The
temperature program was as follows: 80 °C for 0.1 min,
then 30° per min to 245 °C at which point the temper-
ature was held constant for 0.4 min. Data collection
commenced 4 min after injection of the sample. The
GC-MS interface heater, the ion source, and quadrupole
temperatures were maintained at 280, 250, and 100 °C,
respectively. All analyses were performed with the
mass spectrometer operating in electron capture nega-
tive ion (ECNI) mode using methane as reagent gas
(Ultrapure grade, Matheson Gas Products). With the
methane flow on, a source pressure of 1.6 torr (indicat-
ed) was used during these studies.
LC-MS equipment and operating conditions. An HP
1090 liquid chromatograph (Hewlett Packard, Palo
Alto, CA) was used for sample injection and as a
solvent delivery system. Injection volumes were 10 mL
for the plasma and urine samples, and 5 mL for the
synovial fluid samples. Liquid chromatographic sepa-
rations were performed in an Alltima C18 column [150
3 1 mm, 5 mm (Alltech, Deerfield, IL)]. The gradient
used for the separation of the desalted samples was as
follows: a 0–2 min linear ramp from 95% water (solvent
A) and 5% acetonitrile (solvent B) to 25% solvent B and
a 2–6 min linear ramp to 50% B. For the synovial fluid
samples the gradient was adjusted to allow elution of
the salts prior to the compounds of interest. For this
purpose, 0.1% acetic acid was added to solvent A and
the column was eluted with 100% A for 3 min after
sample injection. After the first 3 min the gradient was
as detailed above. To account for the relatively large
dead volume between the solvent delivery system and
the injector, the HPLC pump was operated at 700 mL
min21. A flow splitter was inserted before the injector to
deliver 50 mL min21 to the column (and 650 mL min21 to
waste).
The HPLC column was connected to a Finnigan
TSQ7000 tandem mass spectrometer (MS) via a Finni-
gan electrospray interface (ESI). The electrospray volt-
age was 5.0 kV, the sheath gas pressure was 50 lb/in.2
and the capillary temperature was 250 °C. To obtain
maximum selectivity the mass spectrometer was oper-
ated in the selected reaction monitoring (SRM) mode.
Four precursor-product reactions were monitored: m/z
227 3 181 for 3-nitrotyrosine; 233 3 187 for [13C6]-3-
nitrotyrosine (I.S.); 182 3 136 for tyrosine, and 192 3
145 for [15N1,
13C9]-labeled tyrosine. Argon was used as
collision gas at a collision cell pressure of 1.5 mTorr and
a collision energy of 15 eV.
Results and Discussion
GC-MS Analysis
Our objective was to simultaneously measure 3-nitro-
tyrosine and tyrosine in biological samples so that we
could express 3-nitrotyrosine as a percentage of total
tyrosine residues. Our first attempts at quantifying
3-nitrotyrosine were based on a GC-MS approach and
because 3-nitrotyrosine is a polar molecule, derivatiza-
tion was essential. We elected to prepare a perfluori-
nated derivative to enhance volatility and to impart
electron-capturing properties to the products. In this
way it is possible to take advantage of the intrinsic
sensitivity of electron capture negative ionization mass
spectrometry. Samples were derivatized by treatment
with trifluoroacetic anhydride (TFA) and trifluoretha-
nol (TFE; 4:1, added directly to the dried sample).
Under these conditions 3-nitrotyrosine was converted
to its N-trifluoroacetyl trifluoroethyl ester; there was no
evidence of trifluoroacetylation of the phenolic oxygen
under these conditions. In contrast, tyrosine was con-
verted to its N-,O-bis-trifluoroacetyl trifluoroethyl ester.
The ECNI mass spectrum of derivatized 3-nitrotyrosine
is shown in Figure 1a. It exhibited only two significant
ions: the molecular anion (m/z 404, 100%) and m/z 386
(10%, M2 2 18). In the case of tyrosine, the mass
spectrum showed major ions at m/z 342 (base peak; loss
of NH2COCF3) and m/z 327 (30%, loss of
HCOOCH2CF3) with the molecular anion at m/z 455
(20%) (Figure 1b).
Isotopomers, [13C6]-3-nitrotyrosine and [
15N1,
13C9]-
tyrosine, were employed as internal standards to im-
prove precision by controlling losses during sample
work-up and derivatization. For quantification, two
separate ion pairs were selected for recording in SIM
mode: m/z 404 and 410 (3-nitrotyrosine and its [13C6]-
isotopomer) and m/z 455 and 465 (tyrosine and its [15N1,
13C9]-isotopomer). The on-column limit of quantifica-
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tion for 3-nitrotyrosine was 1 fmol (226 fg) with a signal
to noise ratio of greater than 20:1. The calibration curve
for 3-nitrotyrosine was linear over the range 0–250 fmol
(0–56.5 pg; on column), with a regression equation Y 5
0.040X 2 0.002 and R2 5 0.999 (where Y 5 peak
area ratio m/z 404/410, and X 5 fmol of 3-nitrotyrosine
injected). The derivative was stable over a two week
period and good coefficients of variation were obtained
for standard samples assayed by the GC-MS method.
Artifactual Nitration of Tyrosine in Plasma
Samples Measured by GC/MS
In our initial attempts to quantify nitrotyrosine using
the GC/MS assay we adopted the simple approach of
using both [13C6]-labeled tyrosine and [
13C6]-labeled
3-nitrotyrosine, respectively, to quantify simulta-
neously tyrosine and 3-nitrotyrosine. When the assay
was applied to the measurement of “free” 3-nitroty-
rosine (i.e., not protein bound) in biological samples we
noted problems. Plasma samples (n 5 6) returned a
mean 3-nitrotyrosine level of 0.115 6 0.009 (mmol/L 6
SE). This value was unexpectedly high and represents
approximately 0.16% of the total tyrosine (determined
concurrently) in the sample. Furthermore, we noted an
unexpectedly high abundance of the peak at m/z 410 in
the SIM chromatograms when compared with that
observed for the standard samples. These data indicate
the possibility that both 3-nitrotyrosine and [13C6]-3-
nitrotyrosine were generated in situ from tyrosine and
[13C6]-tyrosine by the action of an unidentified nitrating
species. (Note: this phenomenon was only evident for
Figure 1. (a) The ECNI mass spectrum of the N-trifluoracetyl trifluorethyl ester of 3-nitrotyrosine. (b)
The ECNI mass spectrum of the N,O-bis-trifluoracetyl trifluorethyl ester of tyrosine.
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biological samples, not the standards.) Our suspicions
were confirmed when [15N1,
13C9]-tyrosine was added
to the samples prior to work-up. Under these conditions
[15N1,
13C9]-3-nitrotyrosine was generated from a
plasma sample, but not from a water blank. As indi-
cated below, in all subsequent experiments we adopted
the practice of employing [15N1,
13C9]-labeled tyrosine
to quantify tyrosine, and retained [13C6]-3-nitrotyrosine
for the quantification of 3-nitrotyrosine.
Shigenaga et al. [11] drew attention to the potential
generation of artefactual 3-nitrotyrosine arising from
acid-catalyzed nitration of tyrosine, by nitrite and ni-
trate ions, during hydrolysis with HCl. Ohshima et al.
[16] demonstrated nitration of tyrosine residues in
protein by nitrite under acidic and neutral conditions.
On the basis of these findings we investigated whether
nitrate, which is present in 20–30 mM concentrations in
normal plasma [17], and which might not be completely
removed by the C18 Sep-Pak separation step, could
contribute to the nitration of tyrosine during derivati-
zation in our system. As shown in Figure 2, when
tyrosine (5 nmol) was derivatized with TFAA/TFE in
the presence of varying concentrations of sodium ni-
trate (0–8 nmol/nmol tyrosine), 3-nitrotyrosine was
generated in a dose-related manner. Other data gener-
ated at the time indicated that the presence of acid and
heating facilitated the reaction. There was also evidence
that both the C18 Sep-Pak clean-up step, and the
internal standard itself, [13C6]-3-nitrotyrosine, contrib-
uted some nitrating species that could react with sam-
ple tyrosine to form artifactual 3-nitrotyrosine under
the derivatization condition we employed.
The phenolic group powerfully activates aromatic
rings towards electrophilic substitution, especially to-
wards the ortho position, so tyrosine can readily un-
dergo nitration if appropriate conditions are provided.
Despite being a low yielding reaction (i.e., ;3% maxi-
mum based on the data shown in Figure 2), the propen-
sity to form 3-nitrotyrosine is significant in any situa-
tion where there is a vast excess of the substrate
tyrosine in relation to the 3-nitrotyrosine actually
present in the sample. As a consequence, a major
proportion, if not all of the 3-nitrotyrosine detected in
our samples was being artifactually formed during the
derivatization step.
We attempted to eliminate the artifact by performing
the derivatization reaction in toluene. Whereas these
conditions provided a large excess of an additional site
for electrophilic substitution, and this served to reduce
the extent of artifactual formation, it was not eliminated
completely, and remained a hindrance to accurate
quantification.
Approaches to Accounting for 3-Nitrotyrosine
Generation from Sample Tyrosine and Nitrating
Species
Because 3-nitrotyrosine is readily generated under the
conditions we employed for analyte derivatization, one
approach to avoiding the problem was to remove all
trace of the nitrate and/or tyrosine prior to the deriva-
tization step. However, this is not practical: even if a
small fraction of each remains, substantial artifactual
formation—at least in terms of the 3-nitrotyrosine con-
tent of the sample—is possible. We found that inorganic
nitrate remained after the C18 Sep-Pak cartridge extrac-
tion, and consequently we have assumed that nitrate
present in the original sample is the major nitrating
species responsible for reacting with tyrosine in the
plasma. However, other sources of trace quantities of
nitrate were also suspected.
Rather than extending sample work-up and compro-
mising sensitivity—an approach that was unlikely to
remove all traces of both substrates—we opted to take
advantage of the unique mass selectivity of mass spec-
trometry and add a second isotopomer of tyrosine to
the sample mixture prior to derivatization. This tyro-
sine isotopomer would then form [15N1,
13C9]-3-nitro-
tyrosine with the same propensity as the endogenous
tyrosine, and allow the “true” 3-nitrotyrosine content of
the sample to be calculated (i.e., by subtracting the
amount of 3-nitrotyrosine generated artifactually from
the total 3-nitrotyrosine content of the sample). Al-
though this approach worked in some situations, the
total 3-nitrotyrosine value usually vastly exceeded the
true 3-nitrotyrosine level: i.e., the differences between
the total amount of 3-nitrotyrosine and artifically
formed 3-nitrotyrosine were often insignificant. As a
consequence, errors in the determinations were high,
and negative values were sometimes generated. This
phenomenon markedly reduced the practical utility of
our approach. When standards were prepared and
Figure 2. The formation of 3-nitrotyrosine following derivatiza-
tion (TFAA/TFE) of tyrosine in the presence of increasing
amounts of sodium nitrate.
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analyzed, levels of 3-nitrotyrosine as low as 100 fg/mL
gave a measurable peak in the m/z 404 ion chromato-
gram. In contrast, when biological samples were ana-
lyzed, and correction made for artifactual formation, it
was only when “real” 3-nitrotyrosine levels were .25
pg/mL that meaningful (reproducible) quantitative data
were obtained. Figure 3 shows a set of representative
SIM chromatograms obtained for the analysis of an
extracted human plasma sample used to generate cor-
rected 3-nitrotyrosine data.
Because results from physiological samples were
sometimes ambiguous and subject to large standard
errors, as outlined above, we decided to explore an
approach based on LC/MS/MS. The literature on
3-nitrotyrosine indicated that a limit of detection in
the order of 1 pg (injected) would be adequate for the
analysis of most samples, and this is an achievable
objective by routinely employed LC/MS/MS
approaches. Liquid chromatography permits direct
analysis, so the extremes of temperature and pH that
are associated with derivatization and analysis by
GC-MS methods can be avoided. This minimizes
artifactual 3-nitrotyrosine formation, if not eliminat-
ing it completely, even in the presence of a vast excess
of the substrates.
The LC/MS/MS approach we report here allows
simultaneous quantification of both tyrosine and
3-nitrotyrosine, and has been optimized so that the
3-nitrotyrosine peak shape, and that of [13C6]-labeled
3-nitrotyrosine, were not distorted in the presence of a
huge excess of tyrosine. 3-Nitrotyrosine standards were
prepared up to a concentration of 100 pg/mL and the
resulting calibration curves were linear across the range
0.5 to 100 pg/mL (2.2–442 fmol/mL; r2 5 0.999). The
detection limit (at a S/N 5 5) for standard samples was
0.5 pg/mL (2.2 fmol/mL or 10 fmol on column); for
3-nitrotyrosine in biological samples ;1 pg/mL (4.4
fmol/mL).
Figure 3. The ion chromatograms for tyrosine and nitrotyrosine following the extraction of human
plasma (100 mL). The ion chromatograms correspond to the following species: m/z 414, artifactually
formed [15N1,
13C9]-3-nitrotyrosine; m/z 410, the internal standard [
13C6]-3-nitrotyrosine; m/z 404, the
sum of endogeneous and artifactually formed 3-nitrotyrosine; m/z 465, the internal standard [15N1,
13C9]-tyrosine; and m/z 455 endogenous tyrosine.
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When the LC/MS/MS approach was applied to the
analysis of a series of plasma samples previously exam-
ined by GC-MS, none showed the presence of 3-nitro-
tyrosine. These same samples returned uncorrected
3-nitrotyrosine values of 7–12 pg/mL or 31–53 fmol/mL
when assayed by GC/MS; once corrected for apparent
artifactual formation these values were reduced to
20.2–2 pg/mL (i.e., 20.9–8.8 fmol/mL). Similarly, no
3-nitrotyrosine was found by LC/MS/MS in any of the
urine samples tested. By GC-MS these samples returned
uncorrected 3-nitrotyrosine levels of 10–440 pg/mL
(i.e., 44.2 fmol/mL–1.95 pmol/mL); corrected values
where in the range 231 to 22 pg/mL (or 2137 to 28.8
fmol/mL). [Corrected 3-nitrotyrosine values were calcu-
lated by subtracting the number of moles of 3-nitro-
tyrosine formed artifactually from the total (i.e., mea-
sured) moles of 3-nitrotyrosine. Because these are both
relatively large numbers, and represent a single analyt-
ical determination, the errors associated with the pro-
cedure can result in negative values.]
Artifactual formation was shown not to be an issue
with LC/MS/MS. When samples containing 5 ng/mL
(22 pmol/mL) tyrosine and 50 pg/mL (220 fmol/mL)
I.S., with and without 200 mM NO3
2, were prepared and
analyzed, no 3-nitrotyrosine was detected. (A sample
containing tissue was also included.) To ensure that all
our data were internally consistent we took these same
samples, both with and without added nitrate, and
assayed them by our GC-MS method (i.e., following
evaporation to dryness and derivatization with TFAA/
TFE). By GC-MS, 3-nitrotyrosine was present in the
tissue sample at a level of ;170 pg/mL (752 fmol/mL)
and in the standard sample containing nitrate at a level
of ;440 pg/mL (1.95 pmol/mL). (A trace of 3-nitro-
tyrosine was found by GC/MS in the samples without
nitrate added.) When the trifluoroacetyl/trifluoroethyl
esters were converted back to the free acids (by hydro-
lysis), and again analyzed by LC/MS/MS, the levels of
3-nitrotyrosine were comparable to those measured by
GC-MS (see Figure 4).
Kaur and Halliwell [18] reported 3-nitrotyrosine
levels up to 272 pg/mL (1.2 mmol/L) when employing a
relatively insensitive HPLC analysis with a detection
limit of 50 pg/mL (221 fmol/mL). Based on our detec-
tion limit of 1 pg/mL (4.4 fmol/mL), levels of this
magnitude would be easily detected in our system.
However, we could not detect 3-nitrotyrosine in any of
the synovial fluid samples we analyzed by LC/MS/MS.
Based on our data, 3-nitrotyrosine levels in human
synovial fluid are at least 100-fold lower than those
previously reported. We subsequently spiked each sam-
ple tested with 0, 1, and 5 pg/mL of 3-nitrotyrosine and
then reanalyzed them: these analyses unambiguously
confirmed that levels of 3-nitrotyrosine in the synovial
fluid samples tested was less than 1 pg/mL (4.4 fmol/
mL). The chromatograms generated from a single sub-
ject with active RA, both before and after spiking with
3-nitrotyrosine (Figure 5), demonstrate that levels as
low as 1 pg/mL could be detected and quantified in
synovial fluid samples.
Previous studies [12, 13] report the presence of high
levels (;150 mmol/mol tyrosine) of protein-bound
3-nitrotyrosine in rat heart tissue. When we analyzed
tissue from six rat hearts by LC/MS/MS, no detectable
3-nitrotyrosine was found in any of these. Because these
same samples contained ;10 mg of tyrosine, and, based
on the detection limit of 1 pg/mL for the LC/MS/MS
assay, we estimate the amount of 3-nitrotyrosine
present in the rat heart samples to be less than 200 pg
(,15 mmol/mol tyrosine). These results were consistent
with our GC method after correction was made for
artificial 3-nitrotyrosine formation. Because we had
earlier found evidence that the addition of [13C6]-3-
nitrotyrosine may contribute to artifactual formation of
nitrotyrosine, we decided to add the internal standard
after the acid hydrolysis step. In several separately
performed experiments we had clearly demonstrated
that the hydrolysis procedure did not reduce the
amount of nitrotyrosine measured in the sample [e.g.,
note in Figure 4 that the levels of nitrotyrosine did not
change between method 2 (i.e., GC/MS following
TFAA/TFE derivatization) and method 3 (i.e., LC/
MS/MS following gas phase hydrolysis)]. We add,
however, that we collected protein from the superna-
tant following a 13,000 g spin, and therefore a portion of
the total protein was not contained in the sample we
subsequently analyzed. This may, in part, account for
the difference observed.
With the notable exception of the results recently
Figure 4. 3-Nitrotyrosine levels in three samples as determined
by three separate methods: (1) Direct LC/MS/MS, (2) GC-MS
(following TFAA/TFE derivatization), (3) indirect LC/MS/MS;
samples were first derivatized with TFAA/TFE (as for method 2),
and were then hydrolyzed back to the free amino acids. Samples
A, B, and C were derived following work-up of 20 mL each of the
following solutions: (A) tyrosine in water (5 mg/mL); (B) tissue
culture medium known to contain nitrate, and (C) a mixture of
tyrosine (5 mg/mL) and sodium nitrate (200 nmol/mL). ([13C6]-
3-nitrotyrosine internal standard was added to each sample prior
to work-up.)
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provided by Schwedhelm et al. [14], Table 1 shows that
much higher levels of 3-nitrotyrosine have been re-
ported for normal human plasma, synovial fluid from
patients with rheumatoid arthritis and rat heart tissue.
Using LC/MS/MS we can find no evidence of 3-nitro-
tyrosine at levels greater than 1 pg/mL or 15 mmol/mol
tyrosine. It seems reasonable, therefore, to suggest that
some of the quantitative physiological and pathophys-
iological 3-nitrotyrosine levels reported in the literature
may have been influenced by artifact generation or
inadequate method specificity. Kaur et al. [19] recently
described a 3-nitrotyrosine-like “artifact” occurring in
their analyses based on high performance liquid chro-
matography with electrochemical detection. Although
this compound was not positively identified, it was
clearly established that it was not 3-nitrotyrosine itself.
Our studies lead us to conclude that extreme caution
needs to be exercised in interpreting quantitative data
for 3-nitrotyrosine. The recent work of Schwedhelm et
al. serves to confirm that GC/MS/MS can be employed
to generate artifact-free 3-nitrotyrosine levels, but here a
time-consuming HPLC clean-up step had to be incor-
porated to avoid problems [14].
Facile reaction between tyrosine and nitrate can
result in artifactual 3-nitrotyrosine formation at differ-
ent stages during sample handling and work-up, but
notably where at elevated temperatures and reduced
pH. This phenomenon may have invalidated some of
the published data.
Conclusions
We have developed an accurate and practical LC/
MS/MS assay for trace (femtomole) determination of
3-nitrotyrosine in physiological samples. Our
approaches based on GC-MS were found to have a
drawback associated with the propensity of one of
the derivatization reagents (i.e., TFAA) to catalyze
the nitration of tyrosine by nitrate present in samples.
We investigated milder conditions for derivatization
Figure 5. LC/MS chromatogram for the determination of free 3-nitrotyrosine in synovial fluid of an
RA patient before (A) and after the addition of 1 pg/mL (B) and 5 pg/mL (C) 3-nitrotyrosine before
sample preparation. Upper mass trace shows precursor-product reaction 2333 187 (internal stan-
dard), lower trace shows 2273 181 (3-nitrotyrosine).
Table 1. Levels of 3-nitrotyrosine determined by LC/MS/MS in different sample matrices compared with reported values
Sample matrix LC/MS/MS Reported values
Human plasma ,4.4 nmol/L 31.6 6 6 nmol/L [10]; 2.8 6 0.84 nmol/L [14]
RA synovial fluid ,4.4 nmol/L 0–1.2 mmol/L [18]
Rat cardiac tissue ,15 mmol/mol Try 110–154 mmol/mol [13, 20]
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as well as other derivative types but could not
completely eliminate the problem. Our data indicate
that even traces of residual nitrate (or tyrosine) in the
presence of the other substrate can result in measur-
able artifactual 3-nitrotyrosine formation. As an al-
ternative, we therefore adopted an LC/MS/MS assay
that is sensitive and free from the problems of artifac-
tual formation. This assay has been used to demonstrate
that plasma, synovial fluid, and tissue nitrotyrosine
levels are lower than most previously reported values.
Chemical modification, exposure to reduced pH,
and/or elevated temperatures, can lead to the genera-
tion of artifactual 3-nitrotyrosine in biological samples.
Particular attention should be directed towards control-
ling or avoiding this problem when assessing the sig-
nificance of 3-nitrotyrosine in biological systems.
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